These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 30250142)

  • 1. Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo.
    Gammage PA; Viscomi C; Simard ML; Costa ASH; Gaude E; Powell CA; Van Haute L; McCann BJ; Rebelo-Guiomar P; Cerutti R; Zhang L; Rebar EJ; Zeviani M; Frezza C; Stewart JB; Minczuk M
    Nat Med; 2018 Nov; 24(11):1691-1695. PubMed ID: 30250142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of mtZFNs into Early Mouse Embryos.
    McCann BJ; Cox A; Gammage PA; Stewart JB; Zernicka-Goetz M; Minczuk M
    Methods Mol Biol; 2018; 1867():215-228. PubMed ID: 30155826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulating Mitochondrial DNA Heteroplasmy with Mitochondrially Targeted Endonucleases.
    Mikhailov N; Hämäläinen RH
    Ann Biomed Eng; 2024 Sep; 52(9):2627-2640. PubMed ID: 36001180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MitoTALEN reduces mutant mtDNA load and restores tRNA
    Bacman SR; Kauppila JHK; Pereira CV; Nissanka N; Miranda M; Pinto M; Williams SL; Larsson NG; Stewart JB; Moraes CT
    Nat Med; 2018 Nov; 24(11):1696-1700. PubMed ID: 30250143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo.
    Zekonyte U; Bacman SR; Smith J; Shoop W; Pereira CV; Tomberlin G; Stewart J; Jantz D; Moraes CT
    Nat Commun; 2021 May; 12(1):3210. PubMed ID: 34050192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manipulation of Murine Mitochondrial DNA Heteroplasmy with mtZFNs.
    Nash PA; Minczuk M
    Methods Mol Biol; 2023; 2615():329-344. PubMed ID: 36807802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial DNA heteroplasmy in disease and targeted nuclease-based therapeutic approaches.
    Nissanka N; Moraes CT
    EMBO Rep; 2020 Mar; 21(3):e49612. PubMed ID: 32073748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Manipulation of mtDNA Heteroplasmy: A Shifting Perspective.
    Jackson CB; Turnbull DM; Minczuk M; Gammage PA
    Trends Mol Med; 2020 Jul; 26(7):698-709. PubMed ID: 32589937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Manipulation of Human Mitochondrial DNA Heteroplasmy In Vitro Using Tunable mtZFN Technology.
    Gammage PA; Minczuk M
    Methods Mol Biol; 2018; 1867():43-56. PubMed ID: 30155814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue.
    Silva-Pinheiro P; Nash PA; Van Haute L; Mutti CD; Turner K; Minczuk M
    Nat Commun; 2022 Feb; 13(1):750. PubMed ID: 35136065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current strategies towards therapeutic manipulation of mtDNA heteroplasmy.
    Pereira CV; Moraes CT
    Front Biosci (Landmark Ed); 2017 Jan; 22(6):991-1010. PubMed ID: 27814659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations.
    Gammage PA; Rorbach J; Vincent AI; Rebar EJ; Minczuk M
    EMBO Mol Med; 2014 Apr; 6(4):458-66. PubMed ID: 24567072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Old' genome editors might treat mitochondrial diseases.
    Leslie M
    Science; 2018 Sep; 361(6409):1302. PubMed ID: 30262479
    [No Abstract]   [Full Text] [Related]  

  • 14. Manipulation of mitochondrial genes and mtDNA heteroplasmy.
    Bacman SR; Gammage PA; Minczuk M; Moraes CT
    Methods Cell Biol; 2020; 155():441-487. PubMed ID: 32183972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaining Insight into Mitochondrial Genetic Variation and Downstream Pathophysiology: What Can i(PSCs) Do?
    Moreira JD; Gopal DM; Kotton DN; Fetterman JL
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs.
    Gammage PA; Gaude E; Van Haute L; Rebelo-Guiomar P; Jackson CB; Rorbach J; Pekalski ML; Robinson AJ; Charpentier M; Concordet JP; Frezza C; Minczuk M
    Nucleic Acids Res; 2016 Sep; 44(16):7804-16. PubMed ID: 27466392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of mitochondrial gene-editing strategies and their potential applications in mitochondrial hereditary diseases: a review.
    Gao Y; Guo L; Wang F; Wang Y; Li P; Zhang D
    Cytotherapy; 2024 Jan; 26(1):11-24. PubMed ID: 37930294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease.
    Bayona-Bafaluy MP; Blits B; Battersby BJ; Shoubridge EA; Moraes CT
    Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14392-7. PubMed ID: 16179392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends and prospects in mitochondrial genome editing.
    Phan HTL; Lee H; Kim K
    Exp Mol Med; 2023 May; 55(5):871-878. PubMed ID: 37121968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease.
    Shoop WK; Lape J; Trum M; Powell A; Sevigny E; Mischler A; Bacman SR; Fontanesi F; Smith J; Jantz D; Gorsuch CL; Moraes CT
    Nat Metab; 2023 Dec; 5(12):2169-2183. PubMed ID: 38036771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.